#

+91-9811715635

  • #
  • #
  • #
#
Global Rheumatoid Arthritis Market (2013-2018) - Research and Consulting Firm

Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)

Publish Date:Nov 2013
No. of Pages:64

Format : Adobe Reader (PDF) Instant delivery

US$ 800.00

Scope of the report

The report titled “Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)” provides an in-depth analysis of global rheumatoid arthritis market with special focus on biologics drugs. It also accesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2013-18). Further, key drug manufacturers of the global rheumatoid arthritis market like Abbvie Inc. (Humira), Amgen Inc. (Enbrel), Johnson & Johnson (Remicade), Roche Holdings AG (Actemra) are profiled in the report.

Company Coverage

Abbvie Inc.
Amgen Inc.
Johnson & Johnson
Roche Holdings AG

Executive Summary

Rheumatoid arthritis (RA) is a chronic inflammatory disorder that principally attacks synovial joints. It is one of the most common autoimmune diseases affecting people of all ages and races. RA affects the lining of joints, causing a painful swelling that can eventually result in bone erosion and joint deformity. It also leads to stiffness, and redness in the joints. The main factor causing rheumatoid arthritis remains unknown. However, according to studies around the world some of the genetic and environmental factors are found to be more probable causers.

Treatment of Rheumatoid Arthritis involves frequent drugs administration as RA is a progressive and incurable disease. Drugs used for treatment of RA are classified as first line agents- consisting of non steroidal anti-inflammatory drugs (NSAIDs) and steroids such as glucocorticoids and second line agents- consisting of disease modifying anti-rheumatic drugs such as chloroquine, gold salts, penicillamine, cyclosporine, and several biological agents like TNF-α and interleukin-1 inhibitors.

Global rheumatoid arthritis market is driven by increase in incidences of RA patients, global ageing population and increasing healthcare expenditure by government of various nations. Factors which are affecting pharmaceutical companies are pricing pressure, patent expiries of RA drugs, high costs of treatments involved and escalating R&D costs. The market is characterized by use of auto-injectors by patients for RA treatment, increase in RA cases in women and FDA approvals for RA drugs.

1. Executive Summary

2. Rheumatoid Arthritis: An Introduction

2.1 Rheumatoid Arthritis: Causes
2.2 Rheumatoid Arthritis: Symptoms & Diagnosis

2.2.1 Rheumatoid Arthritis: Symptoms
2.2.2 Rheumatoid Arthritis: Diagnosis

3. Rheumatoid Arthritis Treatment

3.1 Clinical Evolution of Rheumatoid Arthritis Treatment
3.2 Rheumatoid Arthritis: Drugs Treatment

3.2.1 First line agents
3.2.2 Second line agents

4. Global Rheumatoid Arthritis Market Analysis

4.1 Global Rheumatoid Arthritis Treatment Market: Size & Growth (Actual & Forecast)
4.2 Global Rheumatoid Arthritis Treatment Market Analysis

4.2.1 Global Biologics Drugs Market Size (Actual & Forecast)
4.2.2 Global Rheumatoid Arthritis Biologics Drugs Market Share (Actual & Forecast)
4.2.3 Global TNF-α target Antibody Market Size (Actual & Forecast)

5. Global Rheumatoid Arthritis Drug Market Analysis

5.1 Global TNF-α target Drugs Market

5.1.1 Global TNF-α target Market Size by Drugs (Actual & Forecast)
5.1.2 TNF-α target Market Share by Drugs (Actual & Forecast)

5.2 Rheumatoid Arthritis Drugs Market: Regional Analysis

5.2.1 Rheumatoid Arthritis Drugs Market Size in the U.S. (2012)
5.2.2 TNFα Blockers Drugs Market Size in the U.S. (2012)
5.2.3 Rheumatoid Arthritis Drugs Market Size in Korea

6. Global Rheumatoid Arthritis Market: Growth Drivers & Challenges

6.1 Growth Drivers

6.1.1 Increase in Incidence of Patients with Rheumatoid Arthritis
6.1.2 Global Aging Population
6.1.3 Global Healthcare Expenditure

6.2 Challenges

6.2.1 Pricing pressure
6.2.2 Patent Expiries
6.2.3 High Cost of Treatment
6.2.4 High R&D Costs

7. Global Rheumatoid Arthritis Market Trends

7.1 Auto-Injectors for Rheumatoid Arthritis Treatment
7.2 Increase in Rheumatoid Arthritis in Women
7.3 Licensing Deals
7.4 FDA Approvals of Rheumatoid Arthritis Drugs
7.5 Rheumatoid Arthritis Drugs in R&D Pipeline

8. Global Rheumatoid Arthritis Market: Competitive Landscape

9. Company Analysis: Global Rheumatoid Arthritis Market

9.1 AbbVie Inc. (Abbott Laboratories)
9.1.1 Business Overview
9.1.2 Financial Overview
9.1.3 Business Strategies

9.2 Amgen Inc.
9.2.1 Business Overview
9.2.2 Financial Overview
9.2.3 Business Strategies

9.3 Johnson & Johnson Services Inc.
9.3.1 Business Overview
9.3.2 Financial Overview
9.3.3 Business Strategies

9.4 Roche Holdings AG
9.4.1 Business Overview
9.4.2 Financial Overview
9.4.3 Business Strategies 
Figure 1: Normal and Arthritis Joints
Figure 2: Clinical Evolution of Rheumatoid Arthritis Treatment
Figure 3: Rheumatoid Arthritis Drugs Treatment Classification
Figure 4: Global Rheumatoid Arthritis Market Size, 2010-12 (US$ Billions)
Figure 5: Global Rheumatoid Arthritis Market Size Forecast, 2013E-18E (US$ Billions)
Figure 6: Global Rheumatoid Arthritis Biologics Drug Market Size, 2010-12E (US$ Billions)
Figure 7: Global Rheumatoid Arthritis Biologics Drug Market Size Forecast, 2013E-18E (US$ Billions)
Figure 8: Global Rheumatoid Arthritis Biologics Drug Market Share by Types (2013E)
Figure 9: Global Rheumatoid Arthritis Biologics Drug Market Share Forecast (2016E)
Figure 10: Global TNF-α target Rheumatoid Arthritis Antibody Treatment Market Size, 2010-12E
Figure 11: Global TNF-α target Rheumatoid Arthritis Antibody Treatment Market Size Forecast, 2013E-18E
Figure 12: Global TNF-α target Rheumatoid Arthritis Antibody Treatment Market Size by Drug, 2010-12E (US$ Billions)
Figure 13: Global TNF-α target Rheumatoid Arthritis Antibody Treatment Market Size by Drug, 2010-12E (US$ Billions)
Figure 14: Global TNF-α target Rheumatoid Arthritis Antibody Treatment Market Share by Drugs (2012E)
Figure 15: Global TNF-α target Rheumatoid Arthritis Antibody Treatment Market Share by Drugs Forecast (2018E)
Figure 16: Rheumatoid Arthritis Drugs Market Size in the U.S, 2012 (US$ Millions)
Figure 17: TNFα Blockers Drugs Market Size and Share in the U.S., 2012 (US$ Billions)
Figure 18: Rheumatoid Arthritis Drugs Market Size in Korea, 2009-11 (US$ Millions)
Figure 19: Number of Patients of Rheumatoid Arthritis in the U.S., 2010-17E (Billions)
Figure 20: Global Aging Population, 2005-13E (Millions)
Figure 21: Global Healthcare Expenditure, 2005-15E (US$ Trillions)
Table 1: Representative Deals in Global Rheumatoid Arthritis Market
Table 2: FDA-Approved Biologic Agents for Forms of Rheumatoid Arthritis by Indication and Year of Indication Approval
Table 3: Biologic Rheumatoid Arthritis Treatments in Clinical Development or in the Market (FY12)
Table 4: Major Players in the Rheumatoid Arthritis Market
Table 5: Indications and Boxed Warnings for Biologics Used in the Treatment of Rheumatoid Arthritis
Figure 22:  AbbVie Inc. Consolidated Revenue and Humira Sales, 2013Q1-2013Q3 (US$ Billions)
Figure 23:  Amgen Inc. Revenue by Business Segment (2012)
Figure 24:  Amgen Inc. Consolidated Revenue and Enbrel Sales, 2010-12 (US$ Billions)
Figure 25:  Johnson & Johnson Revenue by Business Segment (2012)
Figure 26:  Johnson & Johnson Consolidated and Pharmaceutical Segment Revenue, 2010-12 (US$ Billions)
Figure 27:  Roche Holdings AG Revenue by Business Segment (2012)
Figure 28:  Roche Holdings AG Revenue, 2008-12 (US$ Billions)